Garuda Therapeutics’ Post

View organization page for Garuda Therapeutics, graphic

9,866 followers

What does 2024 hold for #biopharma?   Garuda Therapeutics’ Co-founder, President & CEO Dhvanit Shah expects an increased appetite for off-the-shelf blood stem cell therapies due to their ability to bypass many challenges associated with current treatment options.   Check it out: bit.ly/49BZlfA

  • No alternative text description for this image
Mike Rubin, MD, PhD, CFA

ROP (Return on Potential) is my favorite acronym although I’m an MD, PhD, MBA, CFA & a bunch of other acronyms people think matters. 4x’ing ROP @ Harvard, MIT, & Stanford & Founder/CEO of a multibillion dollar VC firm.

5mo

One of the greatest value propositions we can deliver to patients. Excited for what is ahead for team Garuda.

To view or add a comment, sign in

Explore topics